Aude Houchard
Overview
Explore the profile of Aude Houchard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
304
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Ferolla P, Berruti A, Spada F, Brizzi M, Ibrahim T, Marconcini R, et al.
Neuroendocrinology
. 2022 Aug;
113(3):332-342.
PMID: 36044870
Introduction: Lanreotide autogel (LAN) and temozolomide (TMZ) are guidelines-recommended monotherapies for thoracic neuroendocrine tumors (carcinoids; T-NETs), but prospective data for both combined and monotherapies are lacking. ATLANT (NCT02698410) evaluated efficacy...
12.
Meyer T, Caplin M, Khan M, Toumpanakis C, Shetty S, Ramage J, et al.
J Neuroendocrinol
. 2022 Feb;
34(4):e13096.
PMID: 35132704
CALM-NET was a phase IV exploratory study in the UK that aimed to evaluate if the presence of circulating tumour cells (CTCs) at baseline predicted symptomatic response in patients with...
13.
Bolanowski M, Hubalewska-Dydejczyk A, Kos-Kudla B, Ruchala M, Witek P, Zgliczynski W, et al.
Endokrynol Pol
. 2021 Oct;
72(5):512-519.
PMID: 34647602
Introduction: Patients with acromegaly have substantially reduced quality of life (QoL). This study evaluated QoL in patients with acromegaly treated with lanreotide autogel. Material And Methods: This was a prospective,...
14.
Srirajaskanthan R, Pavel M, Kulke M, Clement D, Houchard A, Keeber L, et al.
Clin Ther
. 2021 Oct;
43(10):1779-1785.
PMID: 34598813
Reported incidences of neuroendocrine tumors (NETs) appear to be increasing, possibly due to greater disease awareness and increased accuracy of diagnosis. Approximately 20% of patients with NETs develop carcinoid syndrome...
15.
Pavel M, Cwikla J, Lombard-Bohas C, Borbath I, Shah T, Pape U, et al.
Eur J Cancer
. 2021 Oct;
157:403-414.
PMID: 34597974
Introduction: This prospective, single-arm, phase 2 study assessed the efficacy and safety of lanreotide autogel (LAN) administered at a reduced dosing interval in patients with progressive neuroendocrine tumours (NETs) after...
16.
Giustina A, Bronstein M, Chanson P, Petersenn S, Casanueva F, Sert C, et al.
J Clin Endocrinol Metab
. 2021 Jul;
106(12):3555-3568.
PMID: 34313752
Context: The SAGIT® instrument (SAGIT) has been developed to enable accurate characterization of acromegaly disease activity. Objective: We evaluated the ability of SAGIT to discriminate acromegaly disease control status. Methods:...
17.
Rinke A, Maintz C, Muller L, Weber M, Lahner H, Pavel M, et al.
Exp Clin Endocrinol Diabetes
. 2021 Jul;
129(7):500-509.
PMID: 34293802
Background: The long-acting somatostatin analog lanreotide autogel is effective in the treatment of patients with neuroendocrine tumors. Objective: To evaluate the long-term treatment response in patients with neuroendocrine tumors receiving...
18.
Stormann S, Schopohl J, Bullmann C, Terkamp C, Christ-Crain M, Finke R, et al.
Exp Clin Endocrinol Diabetes
. 2020 Dec;
129(3):224-233.
PMID: 33285601
Background: Evidence from controlled trials has shown that lanreotide autogel is effective in achieving biochemical and symptom control in patients with acromegaly. However, it is important to better understand the...
19.
Adelman D, Truong Thanh X, Feuilly M, Houchard A, Cella D
Adv Ther
. 2020 Mar;
37(4):1608-1619.
PMID: 32157626
Introduction: Somatostatin analogues are used to treat symptoms and slow tumour progression in patients with neuroendocrine tumours (NETs) and carcinoid syndrome and to reduce hormone secretion and pituitary tumour volume...
20.
Prasad V, Srirajaskanthan R, Toumpanakis C, Grana C, Baldari S, Shah T, et al.
Eur J Nucl Med Mol Imaging
. 2020 Feb;
47(10):2358-2371.
PMID: 32062681
Purpose: PRELUDE aimed to assess use and effectiveness/safety of lanreotide autogel/depot (LAN) combined with Lu-DOTATOC or Lu-DOTATATE (LAN-peptide receptor radionuclide therapy [PRRT]) in patients with progressive neuroendocrine tumours (NETs). Methods:...